Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. (NASDAQ: PULM) on September 27, 2019. The report discloses a material corporate governance event regarding the departure of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
On September 27, 2019, Matthew L. Sherman, M.D., tendered his resignation from the Board of Directors and all Board committees. The resignation is effective January 31, 2020. Dr. Sherman is departing to assume the role of Executive Vice President and Chief Medical Officer at Deciphera Pharmaceuticals, Inc. The Company states this departure is not in connection with any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's resignation.
Key Facts for Investor Verification
- Matthew L. Sherman, M.D., is resigning from the Board effective January 31, 2020.
- The resignation is due to a new executive appointment at Deciphera Pharmaceuticals, Inc.
- The Company explicitly states there is no disagreement with the departing director.
- William Duke, Jr., Chief Financial Officer, signed the report on October 3, 2019.